UPCC 26424: An Analysis of Manufacturing Outcomes with Patient Factors from Multiple Myeloma Patients Prescribed Ciltacabtagene Autoleucel
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
The purpose of this study is to learn how participant factors (such as medical history and manufacturing starting material, also known as Apheresis) can predict successful manufacturing of ciltacabtagene autoleucel (Cilta-cel). This information can be used to potentially improve manufacturing processes and treat more patients with Cilta-cel.
We would like to rely on Sterling IRB as the IRB of record for this study.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 855939
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
